In light of this, we incorporated MAO-A into our docking analysis as a notable therapeutic target for depression, and the outcome disclosed that EA and GA possess greater potential for binding and interacting with active residues of MAO-A than the reference standard antidepressant (phenelzine). The gene discussed is MAOA; the disease is major depressive disorder.